China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) Just Recorded An Earnings Miss And Analysts Are Updating Their Numbers

It's shaping up to be a tough period for China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062), which a week ago released some disappointing annual results that could have a notable impact on how the market views the stock. China Resources Double-Crane PharmaceuticalLtd missed analyst forecasts, with revenues of CN¥11b and statutory earnings per share (EPS) of CN¥1.58, falling short by 5.8% and 5.2% respectively. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Following the latest results, China Resources Double-Crane PharmaceuticalLtd's dual analysts are now forecasting revenues of CN¥11.7b in 2025. This would be a modest 4.0% improvement in revenue compared to the last 12 months. Per-share earnings are expected to rise 7.2% to CN¥1.70. Yet prior to the latest earnings, the analysts had been anticipated revenues of CN¥12.9b and earnings per share (EPS) of CN¥1.84 in 2025. It's pretty clear that pessimism has reared its head after the latest results, leading to a weaker revenue outlook and a small dip in earnings per share estimates.

Check out our latest analysis for China Resources Double-Crane PharmaceuticalLtd

The consensus price target fell 5.1% to CN¥26.17, with the weaker earnings outlook clearly leading valuation estimates.

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the China Resources Double-Crane PharmaceuticalLtd's past performance and to peers in the same industry. We can infer from the latest estimates that forecasts expect a continuation of China Resources Double-Crane PharmaceuticalLtd'shistorical trends, as the 4.0% annualised revenue growth to the end of 2025 is roughly in line with the 4.8% annual growth over the past five years. Compare this with the broader industry (in aggregate), which analyst estimates suggest will see revenues grow 11% annually. So although China Resources Double-Crane PharmaceuticalLtd is expected to maintain its revenue growth rate, it's forecast to grow slower than the wider industry.

The Bottom Line

The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for China Resources Double-Crane PharmaceuticalLtd. Unfortunately, they also downgraded their revenue estimates, and our data indicates underperformance compared to the wider industry. Even so, earnings per share are more important to the intrinsic value of the business. Furthermore, the analysts also cut their price targets, suggesting that the latest news has led to greater pessimism about the intrinsic value of the business.

Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have analyst estimates for China Resources Double-Crane PharmaceuticalLtd going out as far as 2027, and you can see them free on our platform here.

You still need to take note of risks, for example - China Resources Double-Crane PharmaceuticalLtd has 1 warning sign we think you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.